65,437 trials
Healthy
Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 278.460; 288.709; 264.509; 268.814 nmol*h/L…
Hepatitis C, Chronic
Primary: Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1) — 22.0; 8.3; 52.7; 30.0 Percentage of participants — p=0.1002
Healthy
Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) — 286.639; 287.696; 234.052; 221.644 nmol*h/L…
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin…
Bioavailability · Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX. — 428; 499; 479; 520 ng/mL
Prosthetic Joint Infection
Primary: Positive Cultures — 7; 7 cultures
Prostate Adenocarcinoma · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms — 0.045; 0.057 ng/mL — p=0.922
Obesity
Primary: Assessment of % Excess Weight Loss — 45.4 %EWL
Ankylosing Spondylitis
Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
Non-Proliferative Diabetic Retinopathy · Cataract
Primary: Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90…
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Mitral Regurgitation Severity — 0.0; 0.0; 5.6; 38.9 Percentage of participants
Alcohol Drinking
Primary: Mean Heavy Drinking Days Per Week by Medication Group — 1.82; 2.94 Number of heavy drinking days — p=0.001
Stroke · Upper Extremity Hemiplegia · Disorder of Hand
Primary: Number of Patients Who Completed the Hand Rehabilitation Program — 14; 13 participants
Sickle Cell Crisis · Acute Pain
Primary: Maximal Change in NRS Pain Scores as a Percentage of Baseline NRS Pain Score. — -66.4; -61.3; -81.1; -79.8 percent change from baseline NRS score. — p=0.18